Synopsys Q2 FY2026 Earnings Beat Driven by AI and Semiconductor Demand 
NIO CEO Says China’s Auto Industry Has Passed Its Golden Era Amid Weak Car Sales 
Xiaomi Shares Drop After Weak Q1 Earnings Amid Rising Smartphone Costs 
Mega IPOs Like SpaceX and OpenAI Could Reshape S&P 500 and Nasdaq 100 Portfolios in 2026 
Samsung Union Dispute Escalates Over Semiconductor Bonus Vote 
Australia Sues 3M for Over A$2 Billion Over PFAS Firefighting Foam Contamination 
Salesforce Q1 FY2027 Earnings Beat Expectations Despite Soft Q2 Revenue Outlook 
Universal Music Group Rejects Pershing Square Takeover Proposal 
Elon Musk Explores Possible Tesla-SpaceX Merger Amid Growing AI Investments 
Meta Subscription Push Could Add Billions in Recurring Revenue, Says Rosenblatt 
JPMorgan Sees Biotech Sector at Turning Point, Upgrades Top Pharma Stocks 
MongoDB Q1 FY2027 Earnings Beat Expectations, Raises Full-Year Outlook 
SK Hynix Joins $1 Trillion Club as AI Chip Demand Fuels Stock Surge 
Samsung to Invest $1.5 Billion in Vietnam Semiconductor Testing Plant by 2027 
Autodesk Beats Q1 Estimates, Acquires MaintainX for $3.6 Billion 
CTOC Goes Live on Bitget Wallet Trading, Expanding Global Access to AI-Powered Healthcare Data Ecosystem 
Sable Offshore Wins Key Court Battle Over California Oil Pipeline 
Royal Philips (AS: PHG) reaffirmed its full-year 2026 guidance after reporting stronger-than-expected first-quarter results, driven by solid sales growth, improving profit margins, and continued productivity gains despite tariff pressures and rising costs.
The Dutch health technology company posted Q1 2026 group sales of €3.90 billion, slightly above analyst expectations of €3.88 billion. Comparable sales increased 4%, outperforming the market consensus of 3.4%. Philips also reported an adjusted EBITA margin of 9%, ahead of analyst estimates of 8.4%, reflecting operational improvements and cost-saving initiatives.
CEO Roy Jakobs said Philips delivered a strong start to the year with healthy order growth and disciplined execution in a challenging macroeconomic environment. Comparable order intake rose 6%, supported by strong demand in the Diagnosis & Treatment and Connected Care divisions, particularly in North America and Europe.
Philips’ Personal Health segment delivered the best performance during the quarter, with comparable sales growth of 9%, significantly above analyst forecasts. The division’s adjusted EBITA margin climbed to 15.8%, also exceeding expectations.
The Diagnosis & Treatment business recorded 2% comparable sales growth, slightly below forecasts, but profitability improved sharply with an adjusted EBITA margin of 9.8%. Meanwhile, Connected Care remained the weakest segment, posting a 3% sales increase but suffering margin pressure from tariffs and inflation, resulting in a lower-than-expected 2.9% adjusted EBITA margin.
Income from operations rose to €241 million, while operating cash flow reached €188 million. Free cash flow totaled €28 million during the quarter.
Philips maintained its full-year 2026 outlook, forecasting comparable sales growth between 3% and 4.5%, adjusted EBITA margin of 12.5% to 13%, and free cash flow ranging from €1.30 billion to €1.50 billion.
The company also announced plans to repurchase up to 4 million shares worth approximately €91 million to support long-term incentive programs, with completion expected by the fourth quarter of 2028.
